Coherus And STORM Therapeutics Team Up To Study STC-15 Combined With LOQTORZI® (Toripalimab-Tpzi) In Clinical Trial

Coherus BioSciences, Inc. announced a new clinical collaboration with STORM Therapeutics, Ltd. to study STC-15, a METTL3 inhibitor, combined with LOQTORZI (toripalimab-tpzi), a next-generation PD-1 inhibitor. The study is a Phase 1b/2 trial focusing on treating several cancers, including non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma, and endometrial cancer.

Theresa LaVallee, Ph.D., Chief Scientific and Development Officer of Coherus, stated, “We are excited to partner with STORM on the development of the LOQTORZI/STC-15 combination, with patient dosing underway in the Phase 1b/2 study. This collaboration is another example of our strategy for expanding potential LOQTORZI indications beyond NPC through cost-efficient drug supply agreements and evaluating LOQTORZI with novel mechanisms in prioritized tumor types such as NSCLC, HNSCC, and others.”

The Phase 1b part of the study will assess the safety and effectiveness of combining STC-15 with LOQTORZI. The Phase 2 segment will expand to include patients with NSCLC, HNSCC, endometrial cancer, and melanoma, involving up to 188 participants across the United States. As part of the collaboration and supply agreement, Coherus will supply LOQTORZI to STORM, which will act as the sponsor of the clinical trial. Both companies will maintain their commercial rights to their respective drugs, whether used alone or together as combination therapies.